• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.

作者信息

Das Sandeep R, Everett Brendan M, Birtcher Kim K, Brown Jenifer M, Januzzi James L, Kalyani Rita R, Kosiborod Mikhail, Magwire Melissa, Morris Pamela B, Neumiller Joshua J, Sperling Laurence S

出版信息

J Am Coll Cardiol. 2020 Sep 1;76(9):1117-1145. doi: 10.1016/j.jacc.2020.05.037. Epub 2020 Aug 5.

DOI:10.1016/j.jacc.2020.05.037
PMID:32771263
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7545583/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bbc/7545583/4d9fd7e8aaac/nihms-1632613-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bbc/7545583/f1734885e328/nihms-1632613-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bbc/7545583/44aba1f6b8d0/nihms-1632613-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bbc/7545583/4d9fd7e8aaac/nihms-1632613-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bbc/7545583/f1734885e328/nihms-1632613-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bbc/7545583/44aba1f6b8d0/nihms-1632613-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bbc/7545583/4d9fd7e8aaac/nihms-1632613-f0003.jpg

相似文献

1
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.2020年2型糖尿病患者降低心血管风险新型疗法专家共识决策路径：美国心脏病学会解决方案集监督委员会报告
J Am Coll Cardiol. 2020 Sep 1;76(9):1117-1145. doi: 10.1016/j.jacc.2020.05.037. Epub 2020 Aug 5.
2
2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.2018年美国心脏病学会戒烟治疗专家共识决策路径：美国心脏病学会临床专家共识文件特别工作组报告
J Am Coll Cardiol. 2018 Dec 25;72(25):3332-3365. doi: 10.1016/j.jacc.2018.10.027. Epub 2018 Dec 5.
3
2019 Methodology for Creating Expert Consensus Decision Pathways: A Report of the American College of Cardiology.2019年创建专家共识决策路径的方法：美国心脏病学会报告
J Am Coll Cardiol. 2019 Aug 27;74(8):1138-1150. doi: 10.1016/j.jacc.2019.05.035. Epub 2019 Jul 23.
4
2019 Methodology for Heart House Roundtables: A Report of the American College of Cardiology Solution Set Oversight Committee.2019年心脏之家圆桌会议方法：美国心脏病学会解决方案集监督委员会报告
J Am Coll Cardiol. 2019 Aug 27;74(8):1116-1137. doi: 10.1016/j.jacc.2019.05.034. Epub 2019 Jul 23.
5
2017 ACC Expert Consensus Decision Pathway on the Management of Mitral Regurgitation: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.2017ACC 专家共识决策路径：处理二尖瓣反流的管理——美国心脏病学会专家组的报告
J Am Coll Cardiol. 2017 Nov 7;70(19):2421-2449. doi: 10.1016/j.jacc.2017.09.019. Epub 2017 Oct 18.
6
2022 ACC Expert Consensus Decision Pathway for Integrating Atherosclerotic Cardiovascular Disease and Multimorbidity Treatment: A Framework for Pragmatic, Patient-Centered Care: A Report of the American College of Cardiology Solution Set Oversight Committee.2022年美国心脏病学会解决方案集监督委员会关于整合动脉粥样硬化性心血管疾病与多重疾病治疗的专家共识决策路径：实用的、以患者为中心的护理框架报告
J Am Coll Cardiol. 2023 Jan 24;81(3):292-317. doi: 10.1016/j.jacc.2022.08.754. Epub 2022 Oct 25.
7
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.2018年美国心脏病学会专家共识决策路径：2型糖尿病合并动脉粥样硬化性心血管疾病患者降低心血管风险的新型疗法：美国心脏病学会专家共识决策路径特别工作组报告
J Am Coll Cardiol. 2018 Dec 18;72(24):3200-3223. doi: 10.1016/j.jacc.2018.09.020. Epub 2018 Nov 26.
8
2020 Focused Update of the 2017 ACC Expert Consensus Decision Pathway on the Management of Mitral Regurgitation: A Report of the American College of Cardiology Solution Set Oversight Committee.2020 年美国心脏病学会解决方案监督委员会对 2017 年 ACC 专家共识决策路径治疗二尖瓣反流的重点更新：报告
J Am Coll Cardiol. 2020 May 5;75(17):2236-2270. doi: 10.1016/j.jacc.2020.02.005. Epub 2020 Feb 14.
9
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee.2022年美国心脏病学会解决方案集监督委员会关于非他汀类疗法在降低低密度脂蛋白胆固醇以管理动脉粥样硬化性心血管疾病风险中的作用的专家共识决策路径报告。
J Am Coll Cardiol. 2022 Oct 4;80(14):1366-1418. doi: 10.1016/j.jacc.2022.07.006. Epub 2022 Aug 25.
10
ACC Appropriate Use Criteria Methodology: 2018 Update: A Report of the American College of Cardiology Appropriate Use Criteria Task Force.美国心脏病学会适宜使用标准方法：2018年更新版：美国心脏病学会适宜使用标准工作组报告
J Am Coll Cardiol. 2018 Feb 27;71(8):935-948. doi: 10.1016/j.jacc.2018.01.007.

引用本文的文献

1
Exploring the Role of GLP-1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review.探索胰高血糖素样肽-1（GLP-1）类似物在糖尿病足溃疡管理中的作用：一项叙述性和系统性综述
Wound Repair Regen. 2025 Sep-Oct;33(5):e70085. doi: 10.1111/wrr.70085.
2
Characteristics of patients prescribed SGLT-2i and/or GLP-1RA among cardiology clinics in the US: insights from the COORDINATE-diabetes trial.美国心脏病学诊所中开具钠-葡萄糖协同转运蛋白2抑制剂（SGLT-2i）和/或胰高血糖素样肽-1受体激动剂（GLP-1RA）处方的患者特征：来自COORDINATE-糖尿病试验的见解
Am J Prev Cardiol. 2025 Jul 23;23:101058. doi: 10.1016/j.ajpc.2025.101058. eCollection 2025 Sep.
3

本文引用的文献

1
Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.钠-葡萄糖共转运蛋白 2 抑制剂用于预防 2 型糖尿病患者的心血管事件：系统评价和荟萃分析。
J Am Heart Assoc. 2020 Feb 4;9(3):e014908. doi: 10.1161/JAHA.119.014908. Epub 2020 Jan 29.
2
Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial.利拉鲁肽作为钠-葡萄糖共转运蛋白 2 抑制剂治疗控制不佳的 2 型糖尿病患者的附加药物：LIRA-ADD2SGLT2i，一项 26 周、随机、双盲、安慰剂对照试验。
Diabetes Obes Metab. 2020 Jun;22(6):929-937. doi: 10.1111/dom.13978. Epub 2020 Feb 14.
3
Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment.
高效抗肥胖治疗时代的肥胖生活方式医学
Nutrients. 2025 Jul 21;17(14):2382. doi: 10.3390/nu17142382.
4
Patterns of prescription and discontinuation of glucagon-like peptide-1 receptor agonists among patients with irritable bowel syndrome.肠易激综合征患者中胰高血糖素样肽-1受体激动剂的处方和停药模式。
Ann Gastroenterol. 2025 Jul-Aug;38(4):420-427. doi: 10.20524/aog.2025.0971. Epub 2025 Jun 26.
5
A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review.2型糖尿病和心血管疾病十年进展：钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂的进展——综述
Front Endocrinol (Lausanne). 2025 Jul 7;16:1605746. doi: 10.3389/fendo.2025.1605746. eCollection 2025.
6
Efficacy and Safety of GLP-1 Receptor Agonists and SGLT-2 Inhibitors in the Treatment of Diabetes Mellitus and Obesity in Liver Transplant Recipients: A Systematic Review.GLP-1受体激动剂和SGLT-2抑制剂治疗肝移植受者糖尿病和肥胖症的疗效与安全性：一项系统评价
J Clin Med. 2025 Jun 30;14(13):4619. doi: 10.3390/jcm14134619.
7
Impact of multifactorial interventions with medication and lifestyle optimization on patients with type 2 diabetes: A randomised controlled trial.药物治疗与生活方式优化的多因素干预对2型糖尿病患者的影响：一项随机对照试验。
PLoS One. 2025 Jul 9;20(7):e0327211. doi: 10.1371/journal.pone.0327211. eCollection 2025.
8
Preoperative optimization of obese spine patients with GLP-1 receptor agonists: enhancing surgery and improving outcomes.使用胰高血糖素样肽-1受体激动剂对肥胖脊柱患者进行术前优化：增强手术效果并改善预后。
J Spine Surg. 2025 Jun 27;11(2):339-346. doi: 10.21037/jss-24-152. Epub 2025 Apr 14.
9
Association of GLP1-Receptor Agonists with Risk of Hepatocellular Carcinoma: A Retrospective Cohort Study.胰高血糖素样肽-1受体激动剂与肝细胞癌风险的关联：一项回顾性队列研究。
Drug Saf. 2025 Jun 30. doi: 10.1007/s40264-025-01558-1.
10
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome.司美格鲁肽：治疗心血管-肾脏-代谢综合征的关键药物。
Future Cardiol. 2025 Jul;21(9):663-683. doi: 10.1080/14796678.2025.2511412. Epub 2025 Jun 3.
Abridged for Primary Care Providers.为初级保健提供者缩写。
Clin Diabetes. 2020 Jan;38(1):10-38. doi: 10.2337/cd20-as01.
4
Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier's gangrene.真实世界证据：钠-葡萄糖共转运蛋白 2 抑制剂的使用与 Fournier 坏疽风险的关系
BMJ Open Diabetes Res Care. 2020 Jan;8(1). doi: 10.1136/bmjdrc-2019-000985.
5
Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).恩格列净对急性失代偿性心力衰竭（EMPA-RESPONSE-AHF）患者临床结局影响的随机、双盲、安慰剂对照、多中心先导研究。
Eur J Heart Fail. 2020 Apr;22(4):713-722. doi: 10.1002/ejhf.1713. Epub 2020 Jan 7.
6
11. Microvascular Complications and Foot Care: .11. 微血管并发症与足部护理：
Diabetes Care. 2020 Jan;43(Suppl 1):S135-S151. doi: 10.2337/dc20-S011.
7
10. Cardiovascular Disease and Risk Management: .10. 心血管疾病与风险管理： 。
Diabetes Care. 2020 Jan;43(Suppl 1):S111-S134. doi: 10.2337/dc20-S010.
8
Professional Practice Committee: .专业实践委员会：
Diabetes Care. 2020 Jan;43(Suppl 1):S3. doi: 10.2337/dc20-Sppc.
9
Introduction: .引言：.
Diabetes Care. 2020 Jan;43(Suppl 1):S1-S2. doi: 10.2337/dc20-Sint.
10
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).2019 年更新版：《2018 年美国糖尿病协会（ADA）与欧洲糖尿病研究协会（EASD）关于 2 型糖尿病患者高血糖管理的共识报告》。
Diabetes Care. 2020 Feb;43(2):487-493. doi: 10.2337/dci19-0066. Epub 2019 Dec 19.